Tradestie Institutional Equity Comparison Engine

SRZN vs CNTB โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-17 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

SRZN Overall Edge

SRZN Captures Institutional Edge (2โ€“2 Pillars ยท 5โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Surrozen, Inc. Common (SRZN) driven by superior Growth & Margin, Momentum & Technical while CNTB counters with relative strength in Valuation, Options & Structure. Fundamentally, SRZN trades at N/M Forward P/E with -485.4% operating margin (+408.6% YoY revenue) versus CNTB at 0.8x Forward P/E and -2384.5% operating margin (+5666.7% YoY). In options structure, SRZN sits in CONSOLIDATION (5th %ile IV; Dealer Gamma Walls on Pro) against CNTB sits in UNCLASSIFIED (100th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner CNTB
SRZN N/M vs CNTB 0.8x Fwd P/E
Growth & Margin Winner SRZN
Op Margin -485.4% vs -2384.5% ยท YoY +408.6% vs +5666.7%
Momentum & Technical Winner SRZN
1Y +130.6% vs -72.1% ยท 52W Pos 69% vs 1%
Options & Structure Winner CNTB
CONSOLIDATION (5th %ile IV) vs UNCLASSIFIED (100th %ile IV)
SRZN NASDAQ
Surrozen, Inc. Common
Biological Products, (No Disgnostic Substances)
$29.93
-7.38% 1D
Market Cap $602.5M
1M Return +25.57%
1Y Return +130.62%
Forward P/E N/M
Unified AI Score
33.2 / 100 SELL
Tech 50.0 Fund 34.0 Flow 65.0 Mom 40.0
CNTB NASDAQ
Connect Biopharma Holdings Limited Ordinary Shares
Pharmaceutical Preparations
$0.59
-7.94% 1D
Market Cap $42.6M
1M Return -34.21%
1Y Return -72.08%
Forward P/E 0.8x
Unified AI Score
41.0 / 100 SELL
Tech 25.0 Fund 48.0 Flow 66.0 Mom 55.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: SRZN +130.62% CNTB -72.08% Spread: +202.7 pp (SRZN Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period SRZN Revenue CNTB Revenue SRZN Op. Margin CNTB Op. Margin Margin Edge
FY2022 $10M N/A -354.7% N/A SRZN
FY2024 $10M $30M -239.7% -86.2% CNTB
FY2025 $0M $0M -1210.6% -90740.6% SRZN

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: SRZN (5) vs CNTB (4)
Institutional Metric SRZN CNTB Criterion Row Winner
Market Capitalization Scale $602.5M $42.6M Larger Scale SRZN
Trailing P/E Ratio Valuation N/M 0.8x Lower Multiple CNTB
Forward P/E Ratio Valuation N/M 0.8x Lower Multiple CNTB
Revenue Growth (YoY) Growth +408.6% +5666.7% Higher Growth CNTB
Operating Margin (TTM) Profitability -485.4% -2384.5% Higher Margin SRZN
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -62.8% -140.5% Higher ROE SRZN
52-Week Range Position Momentum 69% ($12โ€“$38) 1% ($1โ€“$4) Stronger Trend SRZN
Beta / 30D Volatility Risk Regime 1.28ฮฒ ยท 66% Vol 0.92ฮฒ ยท 68% Vol Lower Realized Risk SRZN
Unified Institutional Score Composite Signal 33.2 / 100 (SELL) 41.0 / 100 (SELL) Higher Composite CNTB

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full SRZN vs CNTB Buy Guide
SRZN CONSOLIDATION
38d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 5th %ile
IV Regime Compressed (<25th %ile)
Live SRZN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CNTB UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 100th %ile
IV Regime Extreme (>80th %ile)
Live CNTB Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither SRZN nor CNTB registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.